Çakır, M. Et Al. 2022. Protective effect of fatty acid amide hydrolase inhibitor URB597 and monoacylglycerol lipase inhibitor KML29 on renal ischemia–reperfusion injury via toll-like receptor 4/nuclear factor-kappa B pathway. INTERNATIONAL IMMUNOPHARMACOLOGY , vol.114 , 1-7.

Çakır, M., Aydın, A., & Tekin, S., (2022). Protective effect of fatty acid amide hydrolase inhibitor URB597 and monoacylglycerol lipase inhibitor KML29 on renal ischemia–reperfusion injury via toll-like receptor 4/nuclear factor-kappa B pathway. INTERNATIONAL IMMUNOPHARMACOLOGY , vol.114, 1-7.

Çakır, Murat, Ali Aydın, And SUAT TEKİN. "Protective effect of fatty acid amide hydrolase inhibitor URB597 and monoacylglycerol lipase inhibitor KML29 on renal ischemia–reperfusion injury via toll-like receptor 4/nuclear factor-kappa B pathway," INTERNATIONAL IMMUNOPHARMACOLOGY , vol.114, 1-7, 2022

Çakır, Murat Et Al. "Protective effect of fatty acid amide hydrolase inhibitor URB597 and monoacylglycerol lipase inhibitor KML29 on renal ischemia–reperfusion injury via toll-like receptor 4/nuclear factor-kappa B pathway." INTERNATIONAL IMMUNOPHARMACOLOGY , vol.114, pp.1-7, 2022

Çakır, M. Aydın, A. And Tekin, S. (2022) . "Protective effect of fatty acid amide hydrolase inhibitor URB597 and monoacylglycerol lipase inhibitor KML29 on renal ischemia–reperfusion injury via toll-like receptor 4/nuclear factor-kappa B pathway." INTERNATIONAL IMMUNOPHARMACOLOGY , vol.114, pp.1-7.

@article{article, author={Murat Çakır Et Al. }, title={Protective effect of fatty acid amide hydrolase inhibitor URB597 and monoacylglycerol lipase inhibitor KML29 on renal ischemia–reperfusion injury via toll-like receptor 4/nuclear factor-kappa B pathway}, journal={INTERNATIONAL IMMUNOPHARMACOLOGY}, year=2022, pages={1-7} }